Five Prime Therapeutics Inc (FPRX) 2013年年度报告「NASDAQ」.pdf

1、FIVE PRIME THERAPEUTICS INCFORM 10-K(Annual Report)Filed 03/26/14 for the Period Ending 12/31/13 AddressTWO CORPORATE DRIVESOUTH SAN FRANCISCO,CA 94080Telephone415-365-5600CIK0001175505SymbolFPRXSIC Code2834-Pharmaceutical PreparationsFiscal Year12/31http:/www.edgar- Copyright 2014,EDGAR Online,Inc.

2、All Rights Reserved.Distribution and use of this document restricted under EDGAR Online,Inc.Terms of Use.Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON,DC 20549 FORM 10-K For the fiscal year ended December 31,2013 or For the transition period from to Commission File Nu

3、mber:001-36070 Five Prime Therapeutics,Inc.(Exact name of registrant as specified in its charter)Two Corporate Drive South San Francisco,California 94080 (415)365-5600 (Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Securities registere

4、d pursuant to Section 12(b)of the Act:Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes?No Indicate by check mark if the registrant is not required to file reports p

5、ursuant to Section 13 or 15(d)of the Act.Yes?No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file s

6、uch reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No?Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and posted pursuant to Rule 405 of R